These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immunohistochemical analysis of platelet-derived growth factor and its receptors in fibrohistiocytic tumors. Taniuchi K; Yamada Y; Nonomura A; Takehara K J Cutan Pathol; 1997 Aug; 24(7):393-7. PubMed ID: 9274955 [TBL] [Abstract][Full Text] [Related]
3. Flow-cytometric DNA analysis in cutaneous fibrohistiocytic tumors. Okita H; Ohtsuka T; Yamazaki S Dermatology; 2003; 207(4):357-61. PubMed ID: 14657626 [TBL] [Abstract][Full Text] [Related]
4. Dermatofibrosarcoma protuberans: an analysis of proliferative activity, DNA flow cytometry and p53 overexpression with emphasis on its progression. Sasaki M; Ishida T; Horiuchi H; MacHinami R Pathol Int; 1999 Sep; 49(9):799-806. PubMed ID: 10504551 [TBL] [Abstract][Full Text] [Related]
5. Microvessel density and HIF-1alpha expression correlate with malignant potential in fibrohistiocytic tumors. Koga K; Nabeshima K; Nishimura N; Shishime M; Nakayama J; Iwasaki H Eur J Dermatol; 2005; 15(6):465-9. PubMed ID: 16280300 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical markers in fibrohistiocytic lesions: factor XIIIa, CD34, S-100 and p75. West KL; Cardona DM; Su Z; Puri PK Am J Dermatopathol; 2014 May; 36(5):414-9. PubMed ID: 24162384 [TBL] [Abstract][Full Text] [Related]
7. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity. Li N; McNiff J; Hui P; Manfioletti G; Tallini G Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855 [TBL] [Abstract][Full Text] [Related]
9. Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions. Agarwal A; Gopinath A; Tetzlaff MT; Prieto VG Am J Dermatopathol; 2017 Jul; 39(7):504-507. PubMed ID: 28609344 [TBL] [Abstract][Full Text] [Related]
10. p53 protein immunoreactivity in fibrohistiocytic tumors of the skin. Lee CS; Chou ST Pathology; 1998 Aug; 30(3):272-5. PubMed ID: 9770192 [TBL] [Abstract][Full Text] [Related]
11. nm23 protein expression and p53 immunoreactivity in cutaneous fibrohistiocytic tumors. Lee CS; Clarke RA; Tran KT; Kearsley JH; Chou ST Pathology; 1999 May; 31(2):123-6. PubMed ID: 10399167 [TBL] [Abstract][Full Text] [Related]
12. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa. Kahn HJ; Fekete E; From L Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295 [TBL] [Abstract][Full Text] [Related]
13. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34. Kim HJ; Lee JY; Kim SH; Seo YJ; Lee JH; Park JK; Kim MH; Cinn YW; Cho KH; Yoon TY Br J Dermatol; 2007 Aug; 157(2):319-24. PubMed ID: 17596171 [TBL] [Abstract][Full Text] [Related]
14. Angiomatoid features in fibrohistiocytic sarcomas. Immunohistochemical, ultrastructural, and clinical distinction from vascular neoplasms. Costa MJ; McGlothlen L; Pierce M; Munn R; Vogt PJ Arch Pathol Lab Med; 1995 Nov; 119(11):1065-71. PubMed ID: 7487409 [TBL] [Abstract][Full Text] [Related]
15. [Differences of the molecular phenotypes and the histogenesis between dermatofibroma and dermatofibrosarcoma protuberans]. Xiong Y; Guo H; Zhang S; Zhang B; Li T Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):395-400. PubMed ID: 18677387 [TBL] [Abstract][Full Text] [Related]
16. The expression levels of thrombospondin-1 in dermatofibroma and dermatofibrosarcoma protuberans. Maekawa T; Jinnin M; Ohtsuki M; Ihn H Eur J Dermatol; 2011; 21(4):534-8. PubMed ID: 21697041 [TBL] [Abstract][Full Text] [Related]
17. IGFBP7, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans. Li J; Yu Y; Yang Y; Wang L; Cao J; Liang X; Xiao X; Tu Y; Chen H J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):382-5. PubMed ID: 21492256 [TBL] [Abstract][Full Text] [Related]
18. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors. Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of matrix metalloproteinases 1, 2, 9, and 14 in dermatofibrosarcoma protuberans and common fibrous histiocytoma (dermatofibroma). Weinrach DM; Wang KL; Wiley EL; Laskin WB Arch Pathol Lab Med; 2004 Oct; 128(10):1136-41. PubMed ID: 15387709 [TBL] [Abstract][Full Text] [Related]
20. The expression levels and the differential expression of transforming growth factor-beta receptors in dermatofibroma and dermatofibrosarcoma protuberans. Kubo M; Ihn H; Yamane K; Tamaki K Br J Dermatol; 2006 May; 154(5):919-25. PubMed ID: 16634896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]